• 137423+ Medical Conferences
  • 251 Specialties
  • 10507 Organizers
  • 151941 Speakers
  • 156 Countries
  • 4563 Cities
CME Conference Registrations Sold
Home  >  Speakers  >  Ravi Kumar Amaravadi
Ravi Kumar Amaravadi

Ravi Kumar Amaravadi

Associate Professor | Philadelphia, Pennsylvania    United States of America
Hematology, Oncology,...More
Spoken at 4 events

Biography :

Dr. Amaravadi is a physician scientist with expertise in autophagy, conducting early phase clinical trials, and clinically treating patients with advanced melanoma. He was one of the first to demonstrate that autophagy is a targetable mechanism of resistance in cancer therapy using animal models. He has translated this finding into 9 phase I/II clinical trials testing hydroxychloroquine (HCQ) as a possible anticancer agent in multiple cancers. The first 6 clinical trials were published and represent the first deliberate attempt to modulate autophagy therapeutically in any disease.
His laboratory published the first evidence that autophagy is elevated in melanoma patient tumors and predicts poor survival. His work on the role of autophagy in melanoma has identified ER stress associated autophagy as a resistance mechanism to BRAF inhibitors. Working with collaborators in Chemistry, his lab has designed, synthesized and characterized a novel autophagy inhibitor Lys05, which is more potent than HCQ in animal models. Dr. Amaravadi is also a recognized melanoma medical oncologist and phase I trialist who has served as the site PI or co-investigator on melanoma clinical trials involving BRAF inhibitors, and first in human phase I clinical trials of novel cancer agents. In 2013 he was appointed co- Leader of the Cancer Therapeutics Program of the Abramson Cancer Center. In 2015 he was inducted into the American Society of Clinical Investigation.

For speaker's contact information - Contact us



Interested Topics

Hematology, Oncology, Medicine, Biochemistry, Cell Biology, Molecular Biology, Cancer Research, Melanoma, Autophagy, Mechanisms of Cell Death, Developmental Therapeutics, Clinical Trials

State Licenses

This section has yet to be updated by the speaker.

Board Certifications

This section has yet to be updated by the speaker.

Professional Association

This section has yet to be updated by the speaker.



Conference Session Materials

The conference session material has yet to be added by the speaker.

Send Message